Evolving concepts in Phase I and II Drug Development for Crohn's Disease.
The highest attrition rates during drug development programs occur at the proof of concept stage. Given the large number of molecules under development for Crohn's disease, a need exists to improve the efficiency of early drug development by fast-tracking promising agents and terminating ineffe...
المؤلفون الرئيسيون: | Jairath, V, Levesque, B, Vande Casteele, N, Khanna, R, Mosli, M, Hindryckx, P, Travis, S, Duijvenstein, M, Rimola, J, Panes, J, D'Haens, G, Sandborn, W, Feagan, B |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
Oxford University Press
2016
|
مواد مشابهة
-
Evolving concepts in phases I and II drug development for Crohn's Disease
حسب: Jairath, V, وآخرون
منشور في: (2016) -
The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
حسب: Sandborn, W, وآخرون
منشور في: (2016) -
Placebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn's disease
حسب: Jairath, V, وآخرون
منشور في: (2016) -
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
حسب: D'Haens, G, وآخرون
منشور في: (2009) -
Biosimilars in IBD: hope or expectation?
حسب: Gecse, K, وآخرون
منشور في: (2013)